TG Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

TG Therapeutics

01/05/2023 14:32

* TG Therapeutics Inc  TGTX.OQ  reported a quarterly
adjusted loss
of 28 cents​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss
of 37 cents per share.
    * Revenue rose 287.1% to $7.80 million from a year ago;
analysts
expected $3.38 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was a
loss
of 28 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * TG Therapeutics Inc shares had risen by 65.1% this
quarter and
gained 109.9% so far this year.
    * The company reported a quarterly loss of $39.23 million.
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $25.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
1 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.37          -0.28          Beat
 Dec. 31 2022      -0.26          -0.39          Missed
 Sep. 30 2022      -0.34          -0.26          Beat
 Jun. 30 2022      -0.51          -0.30          Beat